Home
Live Updates
U.S. FDA ACKNOWLEDGES ASTELLAS RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE : comparemela.com
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA)...
Related Keywords
Japan ,
United States ,
Australia ,
Canada ,
Tokyo ,
Shitara ,
Aichi ,
United Kingdom ,
American ,
America ,
Moitreyee Chatterjee Kishore ,
Naoki Okamura ,
Rare Diseases Information Center ,
Translational Sciences ,
American Cancer Society ,
Japan Ministry Of Health ,
National Institutes Of Health Center ,
Prnewswire Astellas Pharma Inc ,
National Cancer Institute ,
American Society Of Clinical Oncology ,
End Results Program ,
Drug Administration ,
Oncology Development ,
Astellas Pharma Inc ,
Biologics License Application ,
Prescription Drug User Fee Act ,
Senior Vice President ,
Immuno Oncology Development ,
Locally Advanced Unresectable Metastatic Gastric ,
Gastroesophageal Junction ,
South America ,
Clinical Oncology ,
Cancers Symposium ,
Nature Medicine ,
Focus Immuno Oncology ,
Focus Area Approach ,
End Results ,
Gastric Cancer ,
Health National Center ,
Advancing Translational ,
Rare Diseases Information ,
comparemela.com © 2020. All Rights Reserved.